Waystar Considers Sale as Market Value Slumps Amid Software Sector Decline

Waystar, a healthcare software provider known for its payment management technology used by hospitals and doctors, is reportedly exploring strategic options, including a possible sale. This move comes two years after the company went public on the New York Stock Exchange, according to sources familiar with the situation.

The company, which operates out of Lehi, Utah, and Louisville, Kentucky, has enlisted the services of investment bank Evercore to guide the process. However, these discussions are at an early stage, and a sale is not guaranteed, sources cautioned, speaking on condition of anonymity due to the confidential nature of the information.

Market Challenges and Strategic Shifts

Waystar has faced a challenging year, with its market valuation dropping to approximately $4.8 billion after a 24% decline in share price. This downturn aligns with a broader sell-off in the software sector, as investor sentiment shifts amid concerns over potential disruptions from advancements in artificial intelligence, as noted in a Morgan Stanley report from July.

The company has sought to distinguish itself as a technology entity rather than a traditional healthcare services provider, aiming to achieve higher valuations that technology firms typically enjoy. Initially, investors were receptive to this positioning, leading to a surge in share prices from $20 to a peak of $45 in 2025. However, the stock has since faced pressure.

Company Origins and Stakeholder Perspectives

Waystar was established through the 2017 merger of healthcare revenue management companies Zirmed and Navicure. The company was taken public in 2024 by its major stakeholders, including buyout firm EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT remains the largest shareholder with a 13% stake, followed by CPPIB with 10% and BlackRock Institutional Trust Company with 8%, based on data from LSEG.

While EQT and BlackRock declined to comment on the potential sale, CPPIB did not immediately respond to inquiries. Evercore, the investment bank advising Waystar, also did not provide a comment on the ongoing discussions.

Potential Outcomes and Industry Implications

The outcome of Waystar's exploration of options could serve as a barometer for investor interest in the software industry, particularly concerning companies with a focus on healthcare technology. The sector has been under scrutiny due to technological advances and changing investor expectations.

As Waystar navigates through these strategic considerations, the healthcare software industry will be watching closely to see how the company's decisions might reflect broader trends and shifts within the market.